Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Resource Type
Report
Authors
Hänel G; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Schönle A; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Neumann AS; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Nixdorf D; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Philipp N; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Sponheimer M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Leutbecher A; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Emhardt AJ; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Magno G; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Bücklein V; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Eckmann J; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Dunshee D; Genentech Inc., South San Francisco, CA, USA.; Kramar V; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Korfi K; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Colombetti S; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Umaña P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. christian.klein.ck1@roche.com.; Subklewe M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. marion.subklewe@med.uni-muenchen.de.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany. marion.subklewe@med.uni-muenchen.de.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. marion.subklewe@med.uni-muenchen.de.
Source
Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE